Fig. 2
From: Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling
Decreased PLK2 expression is closely associated with poor outcomes in glioma patients. a, Gene expression analysis using TCGA GBM database (*P < .05, with student’s t-test). b, Gene expression analysis with Rembrandt database in different types of glioma versus non-tumor (*P < .05, **P < .01, ***P < .001, with one-way ANOVA followed by Dunnett’s posttest). c, Gene expression analysis with TCGA GBM dataset in different subtypes of GBM versus non-tumor (***P < .001, with one-way ANOVA followed by Dunnett’s posttest). d. Kaplan-Meier analysis for PLK2 expression using GBM patient samples (P < .0001, with log-rank test). e, Kaplan-Meier analysis for PLK2 expression in Rembrandt dataset by dividing glioma samples into 3 groups including PLK2high, PLK2mid, PLK2low (with log-rank test within each comparison)